MedTrace Logo

BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection:

NCT05004038 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-06

No results posted yet for this study

Summary

A phase IIA randomized double-blind placebo-controlled single-centre study of the effect of Bacillus Calmette-Guérin (BCG) vaccination on the HIV latent reservoir

Conditions

Interventions

BIOLOGICAL

BCG Vaccine AJVaccines

Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Johannes Nemeth, Dr. med. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2023-09-01
Completion
2023-09-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05004038 on ClinicalTrials.gov